What is claimed is:

1. A composition comprising a compound of formula (I):



(I)

wherein

L is a direct bond, or an optionally C_{1-4}alkyl substituted radical selected from the group consisting of C_{1-4}alkylene or C_{3-4}alkenylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{3-4}alkynylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{2-4}alkylidene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, aryloxy wherein NR^1R^2 is not attached to the oxygen, arylthio wherein NR^1R^2 is not attached to the sulfur, C_{2-4}alkoxy wherein NR^1R^2 is not attached to the oxygen or a carbon attached to the oxygen, C_{2-4}alkylthio wherein NR^1R^2 is not attached to the sulfur or a carbon attached to the sulfur, and -C_{2-3}alkyl-X-C_{1-2}alkyl- wherein X is O, S or NH and wherein NR^1R^2 is not attached to a carbon attached to X;

p is 0, 1 or 2;

q is 1 or 2; provided that $2 \leq p+q \leq 4$;

R^1 is a substituent independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene;

R^2 is a substituent independently selected from the group consisting of C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} membered carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene;

or R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated 3-13 membered N-linked heterocyclyl, wherein, in addition to the N-linking nitrogen, the 3-13 membered heterocyclyl may optionally contain between 1 and 3 additional heteroatoms independently selected from O, S, and NH;

wherein R^1 and R^2 are optionally and independently substituted with 1-3 substituents selected from the group consisting of *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9-membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O-; and wherein each of the preceding substituents of R^1 and R^2 may optionally have between 1 and 3 substituents independently selected from the group consisting of trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

one of R^3, R^4 and R^5 is G and the other two independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3} alkoxy ;

G is L^2Q;

L^2 is unbranched -$(CH_2)_n$- wherein n is an integer from 1 to 7;

Q is NR^8R^9 wherein R^8 is independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; and R^9 is independently selected from C_{1-6} alkyl, C_{3-6} alkenyl, 3-9 membered carbocyclyl, 3-13 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; or Q is a saturated 3-15 membered N-linked heterocyclyl, wherein, in addition to the N-linking nitrogen, the 3-15 membered heterocyclyl may optionally contain between 1 and 4 additional heteroatoms independently selected from O, S, and NH;

wherein Q is optionally substituted with 1-3 substituents selected (in addition to the preceding paragraph) from the group consisting of *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9-membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O-; and where said substituent groups of Q may optionally have between 1 and 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

R^a are independently C_{1-3} alkyl, triflouromethyl;

m is 0, 1, 2 or 3; and

wherein each of the above alkyl, alkylene, alkenyl, heterocyclyl, cycloalkyl, carbocyclyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents independently selected from methoxy, halo, amino, nitro, hydroxy, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester, tautomer, solvate or amide thereof.

2. A compound of claim 1, wherein NR^1R^2 taken together form substituted or unsubstituted morpholinyl, thiomorpholinyl, piperidinyl, methylpiperidinyl, piperazinyl, N-methylpiperazinyl, dimethylamino, pyrrolidinyl, azatricyclodecanyl, cyclohexylmethylamino, methylphenethylamino, pyridylamino, anilino, diethylamino, methylethylamino, ethylpropylamino, or dipropylamino;

3. A compound of claim 1, wherein NR^1R^2 taken together form a saturated N-linked nitrogen-containing heterocyclyl.

4. A compound of claim 1, wherein NR^1R^2 taken together form a substituent selected from substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, pyrrolinyl, pyrrolidinyl, thiomorpholinyl, and morpholinyl.

5. A compound of claim 1, wherein wherein NR^1R^2 taken together form a substituent selected from N-(C_{1-6} alkyl)piperazinyl, N-phenyl-piperazinyl, 1,3,8-triaza-spiro{4.5}decyl, and 1,4-dioxa-8-aza-spiro{4.5}decyl.

6. A compound of claim 2, wherein NR^1R^2 taken together form a monovalent radical of an amine selected from the group consisting of aziridine, 1,4,7-trioxa-10-aza-cyclododecane, thiazolidine, 1-phenyl-1,3,8-triaza-spiro{4.5}decan-4-one, piperidine-3-carboxylic acid diethylamide, 1,2,3,4,5,6-hexahydro-{2,3'}bipyridinyl, 4-(3-trifluoromethyl-phenyl)-piperazine, 2-piperazin-1-yl-pyrimidine, piperidine-4-carboxylic acid amide, methyl-(2-pyridin-2-yl-ethyl)-amine, {2-(3,4-dimethoxy-phenyl)-ethyl}-methyl-amine, thiomorpholinyl, allyl-cyclopentyl-amine, {2-(1H-indol-3-yl)-ethyl}-methyl-amine, 1-piperidin-4-yl-1,3-dihydro-benzoimidazol-2-one, 2-(piperidin-4-yloxy)-pyrimidine, piperidin-4-yl-pyridin-2-yl-amine, phenylamine, pyridin-2-ylamine.

7. A compound of claim 4, wherein NR^1R^2 taken together form a substituent selected from the group consisting of morpholinyl and piperidinyl, wherein said substituent is optionally substituted with between 1 and 3 substituents selected from hydroxy, halo, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9 membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl.

8. A compound of claim 3, wherein the saturated N-linked nitrogen-containing heterocyclyl is substituted with a substituent selected from the group consisting of pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)C_{1-6} alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)C_{1-6} alkylene, tetrazolyl, (triazolyl)C_{1-6} alkylene, triazolyl, (pyrrolyl)C_{1-6} alkylene, pyrrolidinyl, and pyrrolyl.

9. A compound of claim 1, wherein NR^1R^2 taken together form morpholinyl, piperidinyl, pyrrolidinyl, or diethylamino.

10. A compound of claim 1, wherein Q is morpholinyl, piperidinyl, pyrrolidinyl, or diethylamino.

11. A compound of claim 1, wherein NR^1R^2 taken together form morpholinyl, piperidinyl, or pyrrolidinyl.

12. A compound of claim 1, wherein Q is morpholinyl, piperidinyl, or pyrrolidinyl.

13. A compound of claim 12, wherein NR^1R^2 is a substituted or unsubstituted morpholino.

14. A compound of claim 1, wherein one of R^3 and R^4 is G.

15. A compound of claim 1, wherein R^4 is G.

16. A compound of claim 14, wherein R^3 is G.

17. A compound of claim 1, wherein q is 2 and p is 1.

18. A compound of claim 1, wherein q is 1 and p is 1.

19. A compound of claim 1, wherein q is 2 and p is 2.

20. A compound of claim 1, wherein L is $-CH_2-$.

21. A compound of claim 1, wherein L is a direct bond.

22. A compound of claim 1, wherein L is $-CH_2CH_2-$.

23. A compound of claim 1, wherein L^2 is $-CH_2-$

24. A compound of claim 1, wherein Q is selected from the group consisting of substituted or unsubstituted pyrrolidinyl, piperidinyl, methylpiperidinyl, morpholinyl, thiomorpholinyl, azatricyclodecanyl, cyclohexylamino, cyclohexylmethylamino, piperazinyl, N-methylpiperazinyl, dimethylamino, methylphenethylamino, pyridylamino, anilino, diethylamino, methylethylamino, ethylpropylamino, dipropylamino, or 1,4,7,10-tetraoxa-13-aza-cyclopentadecanyl.

25. A compound of claim 1, wherein Q is a saturated N-linked nitrogen-containing heterocyclyl.

26. A compound of claim 1, wherein Q is a substituent selected from the group consisting of substituted piperidinyl, unsubstituted piperidinyl, substituted piperazinyl, unsubstituted piperazinyl, pyrrolinyl, pyrrolidinyl, thiomorpholinyl, and morpholinyl.

27. A compound of claim 1, wherein substituted Q is N-(C_{1-6} alkyl)piperazinyl, N-phenyl-piperazinyl, 1,3,8-triaza-spiro{4.5}decyl, or 1,4-dioxa-8-aza-spiro{4.5}decyl.

28. A compound of claim 25, wherein Q is a monovalent radical of an amine selected from the group consisting of aziridine, 1,4,7-trioxa-10-aza-

cyclododecane, thiazolidine, 1-phenyl-1,3,8-triaza-spiro{4.5}decan-4-one, piperidine-3-carboxylic acid diethylamide, 1,2,3,4,5,6-hexahydro-{2,3'}bipyridinyl, 4-(3-trifluoromethyl-phenyl)-piperazine, 2-piperazin-1-yl-pyrimidine, piperidine-4-carboxylic acid amide, methyl-(2-pyridin-2-yl-ethyl)-amine, {2-(3,4-dimethoxy-phenyl)-ethyl}-methyl-amine, thiomorpholinyl, allyl-cyclopentyl-amine, {2-(1H-indol-3-yl)-ethyl}-methyl-amine, 1-piperidin-4-yl-1,3-dihydro-benzoimidazol-2-one, 2-(piperidin-4-yloxy)-pyrimidine, piperidin-4-yl-pyridin-2-yl-amine, phenylamine, and pyridin-2-ylamine.

29. A compound of claim 25, wherein Q is morpholinyl, pyridyl, or piperidinyl, and wherein Q is optionally substituted with between 1 and 3 substituents selected from hydroxy, halo, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9 membered or 6-9 membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered or 6-9 membered heterocyclyl), -NH(5-9 membered or 6-9 membered heterocyclyl), -O(5-9 or 6-9 membered heterocyclyl), (5-9 membered or 6-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O- where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl.

30. A compound of claim 29, wherein Q is substituted with a substituent comprising a 5-9 membered heterocyclyl group selected from: pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)C_{1-6} alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)C_{1-6} alkylene, tetrazolyl, (triazolyl)C_{1-6} alkylene, triazolyl, (pyrrolyl)C_{1-6} alkylene, pyrrolidinyl, and pyrrolyl.

31. A compound of claim 30, wherein Q is a substituted or unsubstituted morpholinyl.

32 A compound of claim 1, wherein R^8 is hydrogen.

33. A compound of claim 1, wherein R^8 is C_{1-6} alkyl.

34. A compound of claim 1, wherein R^8 is cyclohexyl.

35. A compound of claim 1, wherein R^8 and R^9 independently are C_{1-6} alkyl.

36. A compound of claim 1, wherein R^8 and R^9 are methyl.

37. A compound of claim 1, wherein R^8 and R^9 are ethyl.

38. A compound of claim 32, wherein R^9 is selected from phenyl or 5-9 membered aromatic heterocyclyl, wherein said phenyl or aromatic heterocyclyl is optionally substituted with 1-3 substituents selected from hydroxy, halo, nitro, cyano, trifluoromethyl, and C_{1-3} alkyl.

39. A compound of claim 38, wherein R^9 is selected from substituted or unsubstituted phenyl, pyridyl, pyrimidyl, furyl, thiofuryl, imidazolyl, (imidazolyl)C_{1-6} alkylene, oxazolyl, thiazolyl, 2,3-dihydro-indolyl, benzimidazolyl, 2-oxobenzimidazolyl, (tetrazolyl)C_{1-6} alkylene, tetrazolyl, (triazolyl)C_{1-6} alkylene, triazolyl, (pyrrolyl)C_{1-6} alkylene, and pyrrolyl.

40. A compound of claim 39, wherein R^9 is substituted or unsubstituted phenyl.

41. A compound of claim 39, wherein R^9 is substituted or unsubstituted pyridyl.

42. A compound of claim 1, wherein:
R^1 and R^2 are independently selected from C_2 alkyl, or taken together with the nitrogen to which they are attached, they form a non-

aromatic 5-6 membered heterocyclyl optionally including an additional heteroatom independently selected from O, S, and NH;

one of R^3, R^4, and R^5 is G and the two remaining are H;

G is L^2Q;

L^2 is methylene;

Q is NR^8R^9 wherein R^8 is independently selected from hydrogen, C_{1-2} alkyl, C_3 alkenyl, C_{5-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; and R^9 is independently selected from C_{1-2} alkyl, C_3 alkenyl, C_{5-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (6-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; or Q is a saturated 3-15 membered N-linked heterocyclyl, wherein, in addition to the N-linking nitrogen, the 3-15 membered heterocyclyl may optionally contain between 1 and 4 additional heteroatoms selected from O, S, and NH;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, heterocyclyl, and carbocyclyl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from methoxy, halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

wherein substituents of Q can be further selected from *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, 5-9-membered heterocyclyl, -NH(6-membered heterocyclyl), -O(6-membered heterocyclyl), C_2-hydroxyalkylene, phenyl, benzyl and, where each of above heterocyclyl, phenyl, and alkyl substituent groups of Q may be optionally substituted with trifluoromethyl;

or a pharmaceutically acceptable salt, ester, tautomer, solvate or amide thereof.

43. A compound of claim 1, wherein

NR^1R^2 taken together form morpholinyl, piperidinyl, pyrrolidinyl, or diethylamino,

p is 1 and q is 2, and

Q is selected from substituted or unsubstituted piperidinyl, piperazinyl, pyrrolinyl, pyrrolidinyl, thiomorpholinyl, and morpholinyl.

44. A compound of claim 1, wherein (a) NR^1R^2 taken together form piperidinyl or pyrrolidinyl, (b) n is 1, (c) p is 1 and q is 2, and (d) Q is selected from morpholinyl and piperidinyl.

45. A compound of claim 1, wherein (a) NR^1R^2 taken together form piperidinyl or pyrrolidinyl, (b) n is 1, (c) p is 1 and q is 2, and (d) Q is selected from morpholinyl and piperidinyl.

46. A compound of claim 44, wherein Q is piperidinyl or substituted piperidinyl.

47. A compound of claim 1, wherein

NR^1R^2 taken together form piperidinyl, pyrrolidinyl, or diethylamino,

n is 1,

p is 1 and q is 2, and

Q is NR^8R^9 and R^8 is H and R^9 is selected from phenyl or aromatic 5-9 membered heterocyclyl, wherein said phenyl or heterocyclyl is optionally substituted with 1-3 substituents selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl.

48. A compound of claim 1 wherein R^a is hydrogen.

49. A compound of claim 1 selected from the group consisting of

4-{2-(4-Piperidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;

Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-azacyclotridecane;

Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Dimethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
1-Methyl-4-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperazine;
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-thiomorpholine;
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;
4-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;
4-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;
4-Pyrrolidin-1-ylmethyl-1-(3-pyrrolidin-1-ylmethyl-phenyl)-piperidine;
1-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;
1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-azacyclotridecane;
Cyclohexyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;
1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidin-4-ol;
1-Methyl-4-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperazine;
4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;
4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;
Dimethyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;
4-{2-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-morpholine;
4-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;
1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;
Cyclohexyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;
Cyclohexyl-methyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;
4-{4-{4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl}-benzyl}-morpholine;
Ethyl-methyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;
4-{1-(4-Morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-morpholine;
4-{4-(4-Pyrrolidin-1-yl-piperidin-1-yl)-benzyl}-morpholine;
1'-(4-Morpholin-4-ylmethyl-phenyl)-{1,4'}bipiperidinyl;
1'-(4-Piperidin-1-ylmethyl-phenyl)-{1,4'}bipiperidinyl;
(4-{1,4'}Bipiperidinyl-1'-yl-benzyl)-pyridin-2-yl-amine;
Phenyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Pyridin-2-yl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

1-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;

(4-Fluoro-phenyl)-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;

4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;

Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;

Methyl-phenethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;

1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-3-trifluoromethyl-benzyl]-piperidine;

1-(2-Nitro-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-piperidine;

4-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-morpholine;

1-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidin-4-ol;

1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-trifluoromethyl-benzyl]-piperidine;

1-Isopropyl-4-[3-methyl-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperazine;

1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine;

1-[3-Methyl-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-pyrrolidine;

1-{1-[4-(4-Pyrrolidin-1-yl-piperidin-1-ylmethyl)-2-trifluoromethyl-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

1-(1-{3-Trifluoromethyl-4-[4-(4-trifluoromethyl-phenyl)-piperidin-1-ylmethyl]-phenyl}-piperidin-4-ylmethyl)-pyrrolidine;

1-{1-[2-Fluoro-4-(4-phenyl-piperidin-1-ylmethyl)-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-dimethyl-amine;

1-[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidine;

13-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-trifluoromethyl-benzyl]-1,4,7,10-tetraoxa-13-aza-cyclopentadecane ditrifluoromethanesulfonate; and

{1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-3-trifluoromethyl-benzyl]-piperidin-4-yl}-methanol.

50. A compound of claim 1 selected from the group consisting of

(4-{1,4'}Bipiperidinyl-1'-yl-benzyl)-pyridin-2-yl-amine;

1'-(4-Morpholin-4-ylmethyl-phenyl)-{1,4'}bipiperidinyl;

1'-(4-Piperidin-1-ylmethyl-phenyl)-{1,4'}bipiperidinyl;

1-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

4-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

1-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-azacyclotridecane;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidin-4-ol;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;

1-Methyl-4-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperazine;

1-Methyl-4-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperazine;

4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;

4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-thiomorpholine;

4-{3-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;

4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;

4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;

4-Pyrrolidin-1-ylmethyl-1-(3-pyrrolidin-1-ylmethyl-phenyl)-piperidine;

4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;

Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Cyclohexyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;

Cyclohexyl-methyl-{1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl}-amine;

Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;

Dimethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Dimethyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;

Methyl-phenethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;

Phenyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

Pyridin-2-yl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;

1-(2-Nitro-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-piperidine;

1-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidin-4-ol;

1-[4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-trifluoromethyl-benzyl]-piperidine;

1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine;

1-[3-Methyl-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-pyrrolidine;

1-{1-[4-(4-Pyrrolidin-1-yl-piperidin-1-ylmethyl)-2-trifluoromethyl-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

1-{1-[2-Fluoro-4-(4-phenyl-piperidin-1-ylmethyl)-phenyl]-piperidin-4-ylmethyl}-pyrrolidine;

[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-dimethyl-amine; and

1-[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidine.

51. A compound of claim 1 selected from the group consisting of

1'-(4-Piperidin-1-ylmethyl-phenyl)-{1,4'}bipiperidinyl;

1-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

4-{1-(4-Piperidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;

1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidin-4-ol;
1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;
1-Methyl-4-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperazine;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-thiomorpholine;
4-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-thiomorpholine;
4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;
4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;
Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Cyclohexyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;
Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;
Dimethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Dimethyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;
Methyl-phenethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;
Pyridin-2-yl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
1-(2-Nitro-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-piperidine;
1-[3-Nitro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidin-4-ol;
1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine;
[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-dimethyl-amine; and
1-[3-Fluoro-4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl]-piperidine.

52. A compound of claim 1 selected from the group consisting of
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;

1-Methyl-4-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperazine;
1-{4-(4-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-piperidine;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-morpholine;
4-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-thiomorpholine;
4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;
4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;
Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Cyclohexyl-{4-(4-pyrrolidin-1-ylmethyl-piperidin-1-yl)-benzyl}-amine;
Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;
Dimethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Methyl-phenethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine;
1-(2-Nitro-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-piperidine; and
1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine.

53. A compound of claim 1 selected from the group consisting of
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidin-4-ol;
1-{1-(4-Pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-piperidine;
4-Pyrrolidin-1-ylmethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidine;
4-{2-{1-(4-Piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-morpholine;
Cyclohexyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Diethyl-{1-(4-pyrrolidin-1-ylmethyl-phenyl)-piperidin-4-ylmethyl}-amine;
Diethyl-{2-{1-(4-piperidin-1-ylmethyl-phenyl)-pyrrolidin-3-yl}-ethyl}-amine; and
1-(2-Methyl-4-pyrrolidin-1-ylmethyl-phenyl)-4-pyrrolidin-1-ylmethyl-pyrrolidine.

54. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically-acceptable excipient.

55. A compound of claim 1 isotopically-labelled to be detectable by PET or SPECT.

56. A method of inhibiting histamine H_3 receptor activity in a subject, comprising administering an effective amount of a compound of claim 1 to a subject in need of such inhibition of histamine H_3 receptor activity.

57. A method of treating a subject having a disease or condition modulated by histamine H_3 receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

58. A method of claim 57, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

59. A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H_1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

60. The method of claim 59 wherein the histamine H_1 receptor antagonist and the compound of claim 1 are present in the same dosage form.

61. A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H_2 receptor and the histamine H_3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H_2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

62. The method of claim 39 wherein the histamine H_2 receptor antagonist and the compound of claim 1 are present in the same dosage form.

63. A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

64. A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

65. A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

66. A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

67. A method for studying disorders mediated by the histamine H_3 receptor, comprising using an ^{18}F-labeled or ^{11}C-labeled compound of claim 1 as a positron emission tomography (PET) molecular probe.

68. A composition comprising a compound of formula (I):



(I)

wherein

L is a direct bond, or an optionally C_{1-4}alkyl substituted radical selected from the group consisting of C_{1-4}alkylene or C_{3-4}alkenylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{3-4}alkynylene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, C_{2-4}alkylidene wherein NR^1R^2 is attached to an sp^3 hybridized carbon, aryloxy wherein NR^1R^2 is not attached to the oxygen, arylthio wherein NR^1R^2 is not attached to the sulfur, C_{2-4}alkoxy wherein NR^1R^2 is not attached to the oxygen or a carbon attached to the oxygen, C_{2-4}alkylthio wherein NR^1R^2 is not attached to the sulfur or a carbon attached to the sulfur, and $-C_{2-3}$alkyl-X-C_{1-2}alkyl- wherein X is O, S or NH and wherein NR^1R^2 is not attached to a carbon attached to X;

p is 0, 1 or 2;

q is 1 or 2; provided that $2 \leq p+q \leq 4$;

R^1 and R^2 are independently selected from hydrogen, C_{1-3} alkyl, allyl, C_{3-8} cycloalkyl, 5-9 membered heterocyclyl, phenyl, and (phenyl)C_{1-3} alkylene, or taken together with the nitrogen to which they are attached, they form a non-aromatic 4-13 membered heterocyclyl optionally including up to two additional heteroatoms independently selected from O, S, and NH; and wherein R^1 and R^2 are optionally and independently substituted with substitutents

selected from the group consisting of trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

one of R^3, R^4 and R^5 is G and the other two independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3} alkoxy ;

G is L^2Q;

L^2 is unbranched $-(CH_2)_n-$ wherein n is an integer from 1 to 7;

Q is NR^8R^9 wherein R^8 is independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{4-9} carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; and R^9 is independently selected from C_{1-6} alkyl, C_{3-6} alkenyl, C_{4-9} membered carbocyclyl, 3-12 membered heterocyclyl, phenyl, (5-9-membered heterocyclyl)C_{1-6} alkylene, and (phenyl)C_{1-6} alkylene; or Q is a saturated 3-15 membered N-linked heterocyclyl, wherein, in addition to the N-linking nitrogen, the 3-15 membered heterocyclyl may optionally contain between 1 and 4 additional heteroatoms independently selected from O, S, and NH;

and wherein Q is optionally substituted with 1-3 substituents selected (in addition to the preceding paragraph) from the group consisting of *tert*-butyloxycarbonyl, hydroxy, halo, nitro, amino, cyano, carboxamide, C_{1-6} alkyl, C_{1-6} acyl, 5-9-membered heterocyclyl, -N(C_{1-6} alkyl)(5-9 membered heterocyclyl), -NH(5-9 membered heterocyclyl), -O(5-9 membered heterocyclyl), (5-9 membered heterocyclyl)C_{1-3} alkylene, C_{1-2}-hydroxyalkylene, C_{1-6} alkoxy, (C_{3-6} cycloalkyl)-O-, phenyl, (phenyl)C_{1-3} alkylene, and (phenyl)C_{1-3} alkylene-O-; and where said substituent groups of Q may optionally have between 1 and 3 substituents independently selected from trifluoromethyl, halo, nitro, cyano, hydroxy, and C_{1-3} alkyl;

R^a are independently C_{1-3} alkyl, triflouromethyl; and

m is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, ester, tautomer, solvate or amide thereof.